Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2022
Asensus Surgical, Inc. (ASXC) reported its third quarter 2022 results, maintaining revenue at $2.6 million year-over-year, driven by over 1,900 procedures performed, a 27% increase from 2021. The company initiated five new Senhance programs and submitted a 510(k) application for pediatric use in the U.S. Operating expenses rose to $17.2 million, leading to a net loss of $18.9 million or $0.08 per share. The firm held $88.3 million in cash and investments as of September 30, 2022, and anticipates initiating 8-10 new Senhance systems in 2022.
- 27% increase in procedures performed year-over-year.
- Submitted FDA application for pediatric indication, expanding market potential.
- Five new Senhance program initiations, indicating strong market demand.
- Awarded 2022 Innovation of the Year for the Intelligent Surgical Unit.
- Operating expenses increased to $17.2 million from $16.7 million year-over-year.
- Net loss widened to $18.9 million compared to $16.1 million in Q3 2021.
- Adjusted net loss increased to $16.9 million from $14.3 million year-over-year.
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2022.
Recent Highlights
- Over 1,900 procedures were performed globally during the nine months ended September 30, 2022, representing growth of
27% over the prior year - Five new Senhance program initiations year to date, 3 in Germany, 1 in Japan, 1 in CIS region
- Submitted FDA 510(k) application for pediatric indication in the U.S.
- Received the Society of Laparoscopic & Robotic Surgeons 2022 Innovation of the Year award for the Intelligent Surgical Unit™(ISU™)
- The Company had cash, cash equivalents, short-term and long-term investments, excluding restricted cash, of approximately
$88.3 million at September 30, 2022
“We are very pleased with what we have accomplished this quarter, with impressive utilization metrics, a growing base of clinical evidence highlighting the benefits of the Senhance system and the ISU, and the growth of our installed base,” said Anthony Fernando, Asensus Surgical President and CEO. “As we have made great progress towards the ongoing development of Performance-Guided Surgery and its suite of digital capabilities, we look forward to continuing to progress the platform to enable safer, more consistent surgery - resulting in better outcomes for hospitals and patients alike.”
Digital Surgery Portfolio Expansion
Expanded Global ISU Machine Vision Capabilities
The Company continues to expand the utilization and applicability of the ISU globally. The Company is seeking CE Mark approval for expanded machine vision capabilities in Europe, which the Company continues to expect to receive in late 2022. The newest ISU features include: real-time 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data while performing surgery. The expanded machine vision capabilities have both U.S. FDA 510(k) clearance and Japanese PMDA approval.
This filing included a review of the entire Senhance System platform, and if successful, would represent one of the first robotic surgical systems to be approved through the new, more rigorous MDR process.
Articulating Instrument Launch
These instruments are currently in a pilot launch in the U.S. and Europe, and the Company continues to expect a full scale commercial launch by the end of 2022. Articulating Instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom.
U.S. Pediatric Regulatory Submission
The Company submitted its 510(k) application for pediatric clearance in the U.S. during the third quarter of 2022. The Senhance System’s unique combination of the 3mm instrumentation with 5mm camera scope combined with haptic feedback make it a unique robotic assisted laparoscopic solution for pediatric surgeries.
Market Development
Procedure Volumes
During the first nine months of 2022, over 1,900 procedures have been completed utilizing the Senhance System, a
When a procedure is performed with a Senhance System, the Company is able to collect robust data, including surgical video. Over time, the accumulation of this digital surgical data library will enable the Company to generate powerful clinical insights that will fuel the development of Performance-Guided Surgery capabilities to help surgeons reduce surgical variability and drive consistently superior surgical outcomes.
Clinical Registry (TRUST)
The Company is leveraging its growing body of real-world clinical data through the utilization of its TRUSTTM clinical registry. The Company believes TRUST is the largest multi-specialty robotic-assisted laparoscopic registry in the industry. The Company continues to grow this body of clinical data to support its commercial strategy as well as help to facilitate an increasing number of high-quality clinical publications demonstrating the value of the Senhance System and Performance-Guided Surgery, with over 2,000 patients enrolled to date. The registered procedures consist of approximately
Clinical Validation
During the quarter, there were three peer-reviewed clinical papers published providing further support for the clinical utility of the Senhance System across a variety of surgical specialties.
These papers can be found at the Company’s website, www.senhance.com/us/resources.
During the quarter, the Company received the Society of Laparoscopic & Robotic Surgeons 2022 Innovation of the Year award for the ISU. Each year, The Society of Laparoscopic & Robotic Surgeons recognizes the most innovative products that have a multidisciplinary application in minimally invasive surgery.
New Program Initiations
During the third quarter, the Company announced four Senhance System initiations:
- Evangelical Hospital Goettingen-Weende in Göttingen, Germany
- Saiseikai Shiga Hospital in Ritto, Japan
- The Clinic for General and Visceral Surgery at the St. Bernhard Hospital in Kamp-Lintfort, Germany
- A hospital in the Commonwealth of Independent States (CIS) region
Subsequent to the end of the third quarter, the Company announced one additional Senhance System initiation, bringing the year to date total to five:
- The Dr. von Hauner Children's Hospital at the Ludwig Maximilians University of Munich, located in Munich, Germany.
For the full year 2022, the Company continues to expect to initiate 8 - 10 new Senhance Surgical Systems.
Third Quarter Financial Results
For the three months ended September 30, 2022, the Company reported revenue of
For the three months ended September 30, 2022, total operating expenses were
For the three months ended September 30, 2022, net loss was
Adjusted net loss is a non-GAAP financial measure. See the reconciliation of GAAP to Non-GAAP Measures below. For the three months ended September 30, 2022, the adjusted net loss was
Balance Sheet Updates
The Company had cash, cash equivalents, short-term and long-term investments, excluding restricted cash of approximately
Conference Call
Asensus Surgical, Inc. will host a conference call on Thursday, November 10, 2022, at 4:30 PM ET to discuss its third quarter 2022 operating and financial results. To listen to the conference call on your telephone, please dial 1-866-652-5200 for domestic callers and 1-412-317-6060 for international callers, and reference conference ID 10171489 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website at https://ir.asensus.com/events-and-presentations.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
- TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance System and our 2022 third quarter results. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether we will be able to continue to progress the Company’s platform to enable safer, more consistent surgery resulting in better outcomes for hospitals and patients alike; whether the Company will receive CE Mark approval for expanded machine vision capabilities in Europe in late 2022; whether the Company’s articulating instruments will undergo a full scale commercial launch by the end of 2022; whether the Company will receive a pediatric clearance for the Senhance Surgical System from the FDA; whether the Company’s TRUST clinical registry is the largest multi-specialty robotic-assisted laparoscopic registry in the industry and whether the Company will continue to grow the Trust registry data to support its commercial strategy; and whether we will initiate 8-10 new Senhance Surgical Systems placements in 2022. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Asensus Surgical, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product | $ | 1,964 | $ | 1,922 | $ | 2,565 | $ | 3,651 | ||||||||
| Service | 335 | 395 | 1,067 | 1,180 | ||||||||||||
| Lease | 264 | 254 | 991 | 925 | ||||||||||||
| Total revenue | 2,563 | 2,571 | 4,623 | 5,756 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Product | 3,057 | 1,993 | 4,316 | 4,671 | ||||||||||||
| Service | 365 | 342 | 1,506 | 1,344 | ||||||||||||
| Lease | 982 | 1,015 | 2,752 | 2,794 | ||||||||||||
| Total cost of revenue | 4,404 | 3,350 | 8,574 | 8,809 | ||||||||||||
| Gross loss | (1,841 | ) | (779 | ) | (3,951 | ) | (3,053 | ) | ||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 6,741 | 4,469 | 20,422 | 12,773 | ||||||||||||
| Sales and marketing | 3,615 | 3,551 | 10,936 | 10,166 | ||||||||||||
| General and administrative | 4,853 | 5,557 | 15,378 | 13,397 | ||||||||||||
| Amortization of intangible assets | 2,398 | 2,804 | 7,601 | 8,533 | ||||||||||||
| Change in fair value of contingent consideration | (416 | ) | 278 | (1,168 | ) | 1,013 | ||||||||||
| Property and equipment impairment | — | — | 432 | — | ||||||||||||
| Total Operating Expenses | 17,191 | 16,659 | 53,601 | 45,882 | ||||||||||||
| Operating Loss | (19,032 | ) | (17,438 | ) | (57,552 | ) | (48,935 | ) | ||||||||
| Other Income (Expense), net: | ||||||||||||||||
| Gain on extinguishment of debt | — | — | — | 2,847 | ||||||||||||
| Change in fair value of warrant liabilities | — | — | — | (1,981 | ) | |||||||||||
| Interest income | 291 | 122 | 806 | 253 | ||||||||||||
| Interest expense | (99 | ) | (65 | ) | (440 | ) | (77 | ) | ||||||||
| Employee retention tax credit | — | 1,311 | — | 1,311 | ||||||||||||
| Other (expense) income, net | (29 | ) | 33 | (261 | ) | (3 | ) | |||||||||
| Total Other Income (Expense), net | 163 | 1,401 | 105 | 2,350 | ||||||||||||
| Loss before income taxes | (18,869 | ) | (16,037 | ) | (57,447 | ) | (46,585 | ) | ||||||||
| Income tax (expense) benefit | (55 | ) | (32 | ) | (224 | ) | 4 | |||||||||
| Net loss | (18,924 | ) | (16,069 | ) | (57,671 | ) | (46,581 | ) | ||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | (18,924 | ) | (16,069 | ) | (57,671 | ) | (46,581 | ) | ||||||||
| Foreign currency translation loss | (1,655 | ) | (931 | ) | (4,018 | ) | (2,397 | ) | ||||||||
| Unrealized gain (loss) on available-for-sale investments | 86 | (53 | ) | (610 | ) | (53 | ) | |||||||||
| Comprehensive loss | $ | (20,493 | ) | $ | (17,053 | ) | $ | (62,299 | ) | $ | (49,031 | ) | ||||
| Net loss per common share attributable to common stockholders – basic and diluted | $ | (0.08 | ) | $ | (0.07 | ) | $ | (0.24 | ) | $ | (0.21 | ) | ||||
| Weighted average number of shares used in computing net loss per common share – basic and diluted | 236,713 | 234,337 | 236,373 | 224,300 | ||||||||||||
Asensus Surgical, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
(Unaudited)
| September 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 13,870 | $ | 18,129 | ||||
| Short-term investments, available-for-sale | 72,481 | 80,262 | ||||||
| Accounts receivable, net | 2,250 | 749 | ||||||
| Inventories | 9,035 | 8,634 | ||||||
| Prepaid expenses | 3,713 | 3,255 | ||||||
| Employee retention tax credit receivable | 1,147 | 1,311 | ||||||
| Other current assets | 1,034 | 957 | ||||||
| Total Current Assets | 103,530 | 113,297 | ||||||
| Restricted cash | 1,107 | 1,154 | ||||||
| Long-term investments, available-for-sale | 1,937 | 37,435 | ||||||
| Inventories, net of current portion | 3,441 | 7,074 | ||||||
| Property and equipment, net | 9,145 | 10,971 | ||||||
| Intellectual property, net | 1,529 | 9,892 | ||||||
| Net deferred tax assets | 227 | 288 | ||||||
| Operating lease right-of-use assets, net | 4,799 | 5,348 | ||||||
| Other long-term assets | 2,938 | 1,014 | ||||||
| Total Assets | $ | 128,653 | $ | 186,473 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 3,637 | $ | 3,448 | ||||
| Accrued employee compensation and benefits | 3,868 | 3,559 | ||||||
| Accrued expenses and other current liabilities | 1,320 | 1,617 | ||||||
| Operating lease liabilities – current portion | 662 | 683 | ||||||
| Deferred revenue | 357 | 543 | ||||||
| Total Current Liabilities | 9,844 | 9,850 | ||||||
| Long Term Liabilities: | ||||||||
| Contingent consideration | 1,203 | 2,371 | ||||||
| Noncurrent operating lease liabilities | 4,630 | 5,006 | ||||||
| Total Liabilities | 15,677 | 17,227 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity | ||||||||
| Common stock 235,218,552 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | 237 | 235 | ||||||
| Preferred stock, | — | — | ||||||
| Additional paid-in capital | 960,676 | 954,649 | ||||||
| Accumulated deficit | (843,045 | ) | (785,374 | ) | ||||
| Accumulated other comprehensive loss | (4,892 | ) | (264 | ) | ||||
| Total Stockholders’ Equity | 112,976 | 169,246 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 128,653 | $ | 186,473 | ||||
Asensus Surgical, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2022 | 2021 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (57,671 | ) | $ | (46,581 | ) | ||
| Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
| Depreciation | 2,481 | 2,416 | ||||||
| Amortization of intangible assets | 7,601 | 8,533 | ||||||
| Amortization of discounts and premiums on investments, net | 556 | 65 | ||||||
| Stock-based compensation | 6,361 | 6,589 | ||||||
| Gain on extinguishment of debt | — | (2,847 | ) | |||||
| Deferred tax expense (benefit) | 224 | (4 | ) | |||||
| Change in inventory reserves | 386 | 377 | ||||||
| Bad debt expense | 9 | — | ||||||
| Property and equipment impairment | 432 | — | ||||||
| Loss on disposal of property and equipment | 97 | — | ||||||
| Change in fair value of warrant liabilities | — | 1,981 | ||||||
| Change in fair value of contingent consideration | (1,168 | ) | 1,013 | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,735 | ) | 113 | |||||
| Inventories | (535 | ) | (1,941 | ) | ||||
| Operating lease right-of-use assets | 237 | (3,174 | ) | |||||
| Prepaid expenses | (693 | ) | 1,220 | |||||
| Employee retention tax credit receivable | 164 | (1,311 | ) | |||||
| Other current and long-term assets | (2,123 | ) | 2,098 | |||||
| Accounts payable | 449 | 1,376 | ||||||
| Accrued expenses | 236 | (588 | ) | |||||
| Deferred revenue | (139 | ) | (81 | ) | ||||
| Operating lease liabilities | (53 | ) | 3,259 | |||||
| Net cash and cash equivalents used in operating activities | (44,884 | ) | (27,487 | ) | ||||
| Investing Activities: | ||||||||
| Purchase of available-for-sale investments | (25,588 | ) | (88,232 | ) | ||||
| Proceeds from maturities of available-for-sale investments | 67,702 | — | ||||||
| Purchase of property and equipment | (904 | ) | (838 | ) | ||||
| Net cash and cash equivalents provided by (used in) investing activities | 41,210 | (89,070 | ) | |||||
| Financing Activities: | ||||||||
| Proceeds from issuance of common stock, net of issuance costs | — | 130,361 | ||||||
| Taxes paid related to net share settlement of vesting of restricted stock units | (350 | ) | (1,058 | ) | ||||
| Proceeds from exercise of stock options and warrants | 18 | 30,838 | ||||||
| Net cash and cash equivalents (used in) provided by financing activities | (332 | ) | 160,141 | |||||
| Effect of exchange rate changes on cash and cash equivalents | (300 | ) | (181 | ) | ||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (4,306 | ) | 43,403 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 19,283 | 17,529 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 14,977 | $ | 60,932 | ||||
| Supplemental Disclosure for Cash Flow Information: | ||||||||
| Cash paid for leases | $ | 729 | $ | 781 | ||||
| Cash paid for taxes | $ | 79 | $ | 63 | ||||
| Supplemental Schedule of Non-cash Investing and Financing Activities: | ||||||||
| Transfer of inventories to property and equipment | $ | 1,293 | $ | 2,156 | ||||
| Reclass of warrant liability to common stock and additional paid-in-capital | $ | — | $ | 2,236 | ||||
| Lease liabilities arising from obtaining right-of-use assets | $ | 316 | $ | 3,857 | ||||
| Asensus Surgical, Inc. |
| Reconciliation of Non-GAAP Measures |
| Adjusted Net Loss and Adjusted Net Loss per Share |
| (in thousands except per share amounts) |
| (Unaudited) |
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
| Net loss attributable to common stockholders (GAAP) | $ | (18,924 | ) | $ | (16,069 | ) | $ | (57,671 | ) | $ | (46,581 | ) | |||||||||||||
| Adjustments | |||||||||||||||||||||||||
| Amortization of intangible assets | 2,398 | 2,804 | 7,601 | 8,533 | |||||||||||||||||||||
| Change in fair value of contingent consideration | (416 | ) | 278 | (1,168 | ) | 1,013 | |||||||||||||||||||
| Property and equipment impairment | — | — | 432 | — | |||||||||||||||||||||
| Gain on extinguishment of debt | — | — | — | (2,847 | ) | ||||||||||||||||||||
| Change in fair value of warrant liabilities | — | — | — | 1,981 | |||||||||||||||||||||
| Employee retention tax credit | — | (1,311 | ) | — | (1,311 | ) | |||||||||||||||||||
| Adjusted net loss attributable to common stockholders (Non-GAAP) | $ | (16,942 | ) | $ | (14,298 | ) | $ | (50,806 | ) | $ | (39,212 | ) | |||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
| Net loss per share attributable to common stockholders (GAAP) | $ | (0.08 | ) | $ | (0.07 | ) | $ | (0.24 | ) | $ | (0.21 | ) | |||||||||||||
| Adjustments | |||||||||||||||||||||||||
| Amortization of intangible assets | 0.01 | 0.01 | 0.03 | 0.04 | |||||||||||||||||||||
| Change in fair value of contingent consideration | 0.00 | 0.01 | 0.00 | 0.01 | |||||||||||||||||||||
| Property and equipment impairment | — | — | 0.00 | — | |||||||||||||||||||||
| Gain on extinguishment of debt | — | — | — | (0.01 | ) | ||||||||||||||||||||
| Change in fair value of warrant liabilities | — | — | — | 0.01 | |||||||||||||||||||||
| Employee retention tax credit | — | (0.01 | ) | — | (0.01 | ) | |||||||||||||||||||
| Adjusted net loss per share attributable to common stockholders (Non-GAAP) | $ | (0.07 | ) | $ | (0.06 | ) | $ | (0.21 | ) | $ | (0.17 | ) | |||||||||||||
The non-GAAP financial measures for the three and nine months ended September 30, 2022 and 2021, which provide management with additional insight into the Company’s results of operations from period to period without non-cash charges and are calculated using the following adjustments:
a) Intangible assets that are amortized consist of developed technology and purchased patent rights recorded at cost and amortized over 7 to 10 years.
b) Contingent consideration in connection with the acquisition of the Senhance System in 2015 is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, revenue volatility, EURO to USD exchange rate, and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.
c) Property and equipment impairment associated with returned Senhance Systems under operating leases that are not expected to generate future cash flows sufficient to recover their net book value.
d) During the second quarter of 2021, the Company received notification from the U.S. Small Business Administration that the principal amount of its Paycheck Protection Program loan of
e) The Company’s Series B Warrants were measured at fair value using a simulation model which took into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued upon exercise and the final change in fair value was recognized in the first quarter of 2021.
f) During the third quarter of 2021, the Company submitted a refund for incurred employee payroll taxes of
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
OR
MEDIA CONTACT:
Isabella Rodriguez, 708-833-1572
CG Life
irodriguez@cglife.com
FAQ
What were Asensus Surgical's Q3 2022 financial results?
How many procedures were performed using the Senhance System in Q3 2022?
What new initiatives did Asensus Surgical announce?
What is the expected guidance for new Senhance systems?
What is the current cash position of Asensus Surgical?
